ABBV · 8-K · 20261030PR000033

Guidance / Outlook

AbbVie Inc. · 2026-10-30 · Importance 57 · Surprise 60 · In source text

AbbVie raised its full-year 2026 adjusted diluted EPS guidance from $13.76–$13.96 to $13.95–$13.99. The updated range includes an unfavorable $0.69 per-share impact from acquired IPR&D and milestone expense incurred through the third quarter of 2026. It excludes acquired IPR&D and milestone expense that may be incurred after the third quarter because those costs cannot be reliably forecasted.

Key facts

• AbbVie expects additional lutikizumab INTREPID data, including a 36-week blinded extension, next year and plans to use them to support regulatory submissions for hidradenitis suppurativa in the second half of 2027. source
• AbbVie said findings support advancing ABBV-295 into Phase 2 development for chronic weight management. source
• AbbVie raised 2026 adjusted diluted EPS guidance from $13.76–$13.96 to $13.95–$13.99, including a $0.69-per-share unfavorable impact from acquired IPR&D and milestones expense incurred year-to-date through Q3 2026. source
• AbbVie's 2026 adjusted diluted EPS guidance excludes acquired IPR&D and milestones expense that may be incurred after Q3 2026 because those costs cannot be reliably forecast. source

Impact estimates